Article
Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.
AIDS (London, England) - 2 Jan 2013
Anta Lourdes, Llibre Josep M, Poveda Eva, Blanco José L, Alvarez Marta, Pérez-Elías María J, Aguilera Antonio, Caballero Estrella, Soriano Vicente, de Mendoza Carmen
Abstract excerpt
OBJECTIVE: Rilpivirine (RPV) is the latest approved nonnucleoside reverse transcriptase inhibitor (NNRTI). It displays in-vitro activity extending over other NNRTI-resistant HIV strains. There is scarce information about the rate of RPV resistance-associated mutations (RAMs) in patients failing other NNRTIs. METHODS: RPV RAMs were examined in plasma samples collected from HIV patients that had recently failed...
Topics
Join the communities discussing this publication.